The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of CSPC Innovation Pharmaceutical Co., Ltd. 石藥創新製藥股份有限公司 (the "Company") (A joint stock company incorporated in the Pe ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of Sichuan Biokin Pharmaceutical Co., Ltd. 四川百利天恒藥業股份有限公司 This Post Hearing Inform ...

Antengene Pipeline Overview - Antengene is developing a diverse pipeline of Antibody Drug Conjugates (ADCs), Immuno-Oncology (IO) therapies, and treatments for Autoimmune Diseases [16, 102] - The company's "2+1" T Cell Engager (TCE) platform, AnTenGager, is designed with steric hindrance-masking technology to enhance therapeutic effect and safety [20, 109] ATG-022 (Claudin 18.2 ADC) - ATG-022, a Claudin 18.2 ADC, has shown efficacy across various CLDN18.2 expression levels in gastric cancer [20, 32, 48] - In CLDN18.2 moderate to high expressing GC (IHC 2+ > 20%) patients treated with ATG-022 at 2.4 mg/kg, the ORR was 40% (12/30), and the DCR was 90% (27/30) [20] - In CLDN18.2 low and ultra-low expressing GC (IHC 2+ ≤ 20%) patients, an efficacious dose range of 1.8-2.4 mg/kg of ATG-022 resulted in an ORR of 33.3% (6/18) and a DCR of 50% (9/18) [20] - The median progression-free survival (mPFS) in Gastric or GEJ Cancer with Moderate to High CLDN18 2 Expression (IHC 2+, >20%) Treated at 2 4 mg/kg is 6 97 months, with a 6-month progression-free survival (PFS6m) rate of 51 1% [53] - The company is planning to investigate ATG-022 in combination with Pembrolizumab and CAPOX in Advanced / Metastatic Claudin 18 2 Positive Gastric Cancer (1L) [64] - ATG-022 is estimated to have over US$5 billion in peak sales potential [68, 70] ATG-037 (Oral CD73 Small Molecule Inhibitor) - ATG-037, an oral CD73 small molecule inhibitor, has demonstrated efficacy in CPI-resistant Melanoma with an ORR of 36.4% (4/11) and a DCR of 100% (11/11) [20] - In CPI-resistant Non-small Cell Lung Cancer, ATG-037 showed an ORR of 21.4% (3/14) and a DCR of 71.4% (10/14) [20] - The Immuno-oncology (IO) market is estimated to be $140+ billion in 2028 [78] AnTenGager TCE Platform - ATG-201, a CD19 x CD3 TCE, is IND-enabling for B Cell Driven Autoimmune Diseases, demonstrating deep B cell depletion with low CRS [16, 20, 119] - ATG-106 (CDH6 x CD3) is a First-in-Class CDH6 TCE for Ovarian Cancer and Kidney Cancer [17, 103, 132]